• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

20.59 +2.20 (+11.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,911,286
Open 18.72
Bid (Size) 20.16 (200)
Ask (Size) 20.50 (700)
Prev. Close 18.39
Today's Range 18.67 - 22.22
52wk Range 6.500 - 65.80
Shares Outstanding 66,956,800
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
June 08, 2026
From Vor Biopharma
Via GlobeNewswire

Performance

YTD
+76.9%
+76.9%
1 Month
+43.8%
+43.8%
3 Month
+26.6%
+26.6%
6 Month
+94.6%
+94.6%
1 Year
-61.4%
-61.4%

More News

Read More
News headline image
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 08, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From Vor Biopharma
Via GlobeNewswire
VOR Shares Rally Over 40%In Pre-Market Trade After JPMorgan Initiates Bullish Coverage ↗
December 09, 2025
Via Stocktwits
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
May 30, 2026
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
May 30, 2026
Via The Motley Fool
News headline image
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
May 14, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 30, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
March 30, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
What's Behind The Jump In Vor Biopharma Stock? ↗
March 27, 2026
Via Benzinga
News headline image
Vor Bio Announces $75 Million Private Placement with TCGX
March 27, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 23, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
February 23, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
December 23, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces $150 Million Private Placement
December 15, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
What's going on in today's session ↗
December 09, 2025
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
December 09, 2025
Via Chartmill
News headline image
Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch ↗
December 09, 2025
Via Stocktwits
Topics ETFs Economy Government
News headline image
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From Vor Biopharma
Via GlobeNewswire

Frequently Asked Questions

Is Vor Biopharma Inc. - Common Stock publicly traded?
Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
What exchange does Vor Biopharma Inc. - Common Stock trade on?
Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
What is the current price of Vor Biopharma Inc. - Common Stock?
The current price of Vor Biopharma Inc. - Common Stock is 20.59
When was Vor Biopharma Inc. - Common Stock last traded?
The last trade of Vor Biopharma Inc. - Common Stock was at 07/02/26 04:00 PM ET
What is the market capitalization of Vor Biopharma Inc. - Common Stock?
The market capitalization of Vor Biopharma Inc. - Common Stock is 1.38B
How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
Vor Biopharma Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap